Simparica (Sarolaner) Chewables for Dogs 5–10kg
Fast-acting monthly protection against fleas and ticks in a tasty chew.
Simparica is a flavorful, once-a-month chewable tablet designed to protect dogs from fleas and ticks for a full 30 days. Suitable for dogs weighing 5–10 kg, Simparica starts killing fleas within 3 hours and ticks within 8 hours of administration. It’s an easy, stress-free alternative to topical treatments no mess, no residue, just simple dosing your dog will love.
Simparica works even after bathing or swimming and remains effective for a month. It helps treat and prevent flea infestations and provides consistent tick control, including protection against brown dog ticks, lone star ticks, and black-legged ticks.
Key Benefits:
- Starts killing fleas fast — within 3 hours
- Eliminates ticks quickly — within 8 hours
- Monthly chewable with broad-spectrum coverage
- Stays effective through baths and water exposure
- Tasty, easy-to-administer chew
Dosage & Administration:
- Administer orally once a month with or without food
- This chew is specifically formulated for dogs weighing 5–10 kg
- Ensure accurate dosing based on your dog’s weight
Active Ingredient:
Sarolaner – A powerful isoxazoline compound that disrupts the nervous system of fleas and ticks, leading to rapid death.
Possible Side Effects:
Reported side effects are uncommon but may include:
- Vomiting
- Diarrhea
- Lethargy
- Tremors
- Loss of appetite
- Incoordination (ataxia)
Precautions:
- Use with caution in dogs with a history of seizures or neurological disorders
- Not for use in puppies under 8 weeks of age or weighing less than 1.3 kg
- For dog use only – not safe for cats
Storage Instructions:
- Store below 30°C
- Keep in original packaging until use
- Do not use after the expiry date stated on the label
Compare With:
Simparica offers fast-acting monthly protection and is often compared to other leading brands like NexGard and Bravecto with the added benefit of rapid onset and consistent protection.











Reviews
There are no reviews yet.